Xcell Therapeutics (XKRX:373110) Total Liabilities : ₩7,931 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Xcell Therapeutics Total Liabilities?

Xcell Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 was ₩7,931 Mil.

Xcell Therapeutics's quarterly Total Liabilities declined from Mar. 2024 (₩9,894.53 Mil) to Jun. 2024 (₩9,325.96 Mil) and declined from Jun. 2024 (₩9,325.96 Mil) to Sep. 2024 (₩7,931.09 Mil).

Xcell Therapeutics's annual Total Liabilities declined from Dec. 2021 (₩7,477.00 Mil) to Dec. 2022 (₩7,025.62 Mil) but then increased from Dec. 2022 (₩7,025.62 Mil) to Dec. 2023 (₩8,084.75 Mil).

Xcell Therapeutics Total Liabilities Historical Data

The historical data trend for Xcell Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcell Therapeutics Total Liabilities Chart

Xcell Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

14,326.53

13,435.56

7,477.00

7,025.62

8,084.75

Xcell Therapeutics Quarterly Data
	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial			-	8,084.75	9,894.53	9,325.96	7,931.09

Xcell Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Xcell Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5442.542	+	(1843.402	+	475.679
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	323.126)
	=	8,085

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	10468.253	-	2383.504
	=	8,085

Xcell Therapeutics's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5001.987	+	(1744.861	+	624.794
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	559.449)
	=	7,931

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	19254.279	-	11323.188
	=	7,931

Xcell Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Xcell Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Xcell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xcell Therapeutics Inc (XKRX:373110) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

333, Yeongdong-daero, Gangnam-gu, Seoul, KOR, 06188

Website

http://www.xcell.media

Xcell Therapeutics Inc operates as a research company engaged in development of regenerative medicines. The company is developing proliferation media for various animal cell types.

Xcell Therapeutics Headlines

No Headlines